SABS SAB Biotherapeutics, Inc.: institutional ownership and insider trading
90 funds reported holding $275M of SAB Biotherapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net sold $3.91M, with 28 new positions and 21 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
Famous investors holding SABS
- Izzy Englander (Millennium Management): $10.7M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $837K, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $561K, 0.0% of the portfolio
Largest institutional holders of SABS
- Caligan Partners LP — $31.1M
- Vivo Capital, LLC — $28.5M
- PERCEPTIVE ADVISORS LLC — $25.8M
- ADAGE CAPITAL PARTNERS GP, L.L.C. — $25.0M
- RA CAPITAL MANAGEMENT, L.P. — $17.2M
- BALYASNY ASSET MANAGEMENT L.P. — $14.7M
- BlackRock, Inc. (BLK) — $12.0M
- VANGUARD CAPITAL MANAGEMENT LLC — $11.6M
- Commodore Capital LP — $11.2M
- MILLENNIUM MANAGEMENT LLC — $10.7M
5%+ owners
- JOHNSON DAVID EDWARD: 10.4% (Schedule 13G, filed May 15, 2026)
- Vivo Opportunity Fund Holdings, L.P.: 10.0% (Schedule 13G/A, filed Aug 14, 2026)
- RA Capital Management, L.P.: 9.9% (Schedule 13D/A, filed Aug 10, 2026)
- Commodore Capital LP: 9.9% (Schedule 13G/A, filed Aug 14, 2026)
- BALYASNY ASSET MANAGEMENT L.P.: 9.5% (Schedule 13G/A, filed Aug 14, 2026)
- Caligan Partners LP: 8.8% (Schedule 13G/A, filed Aug 14, 2026)